After first describing the promoter region and expression regulation of MACC1 in CRC (16) we identified mevastatin as transcriptional inhibitor of MACC1 expression in a high-throughput drug screening, and confirmed the same effect for the FDA-approved lovastatin in vitro, as well as in xenograft mouse models for metastasis formation (17). Here, MACC1 is linked to colorectal carcinoma.